Bacteriophage--a common divergent therapeutic approach for Alzheimer's disease and type II diabetes mellitus.
Alzheimer's disease, the most important neurodegenerative disorder, is an irreversible, age-dependent disease of the brain characterized by problems in progressive impairments in memory, language, reasoning, behavior and visuospatial skills. It is characterized by the deposition of amyloid beta peptide, forming compact fibrillar plaques and neurofibrillary tau tangles. Another major and much more prevalent cause of morbidity and mortality in world is diabetes especially type 2 diabetes mellitus. It is caused by a combination of resistance to insulin action and an inadequate compensatory insulin secretory response. Chronic wounds caused by antibiotic resistant bacterial infections that fail to heal are a common complication of diabetes mellitus and the most frequent reason for nontraumatic lower limb amputation. Holistically, these two diseases are linked at molecular level but the exact mechanism is a topic of debate. Bacteriophages are viruses infecting bacteria and lack ability to infect mammalian cells. They are neither causative agent for Alzheimer's disease or type 2 diabetes mellitus nor involved in their pathogenicity but promises for a novel divergent therapeutic approach. The great versatility of the phage system has led to the development of improved phage delivery vectors, as well as immunomodulation of anti-amyloid beta peptide response. Phages could also constitute valuable prophylaxis against bacterial infections, especially in immunocompromised patients like in the case of diabetes. Patients having diabetes have a high risk of developing foot ulcers which are difficult to be treated by antibiotics alone due to ever increasing antibiotic resistance strains. Combination therapy based on multiple phage and broad spectrum antibiotics holds great promise. The potential therapeutic phage therapy arises from its lack of natural tropism for mammalian cells, resulting in no adverse effects.
Sayed S
SS
Sohrab
Sajjad
S
Karim
Mohammad A
MA
Kamal
Adel M
AM
Abuzenadah
Adeel G
AG
Chaudhary
Mohammed H
MH
Al-Qahtani
Proteomics and Structural Biology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, Post Box No- 80216, Jeddah - 21589, Saudi Arabia. zmirza1@kau.edu.sa.
Zeenat
Z
Mirza
D000544:Alzheimer Disease / Q000276:immunology / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000628:therapy*; D001435:Bacteriophages / Q000502:physiology*; D003924:Diabetes Mellitus, Type 2 / Q000276:immunology / Q000628:therapy*; D006801:Humans
D016229:Amyloid beta-Peptides; D000900:Anti-Bacterial Agents